Skip to main content
Premium Trial:

Request an Annual Quote

Ulf Jonsson, Udo Klein, and Chad Mirkin

Premium

Cellectricon has appointed Ulf Jonsson as chief executive officer, effective Jan. 1, 2005, it said last week.

Jonsson will be replacing Jakob Lindberg, one of the company’s co-founders, who recently announced his planned resignation.

Jonsson previously served as CEO of Biacore. He has also worked for Pharmacia Biotechnology/Amersham Bioscience as a marketing manager for molecular biological systems. He holds a PhD in applied physics.

Cellectricon, based in Gothenburg, Sweden, raised SEK 53 million (about $7 million) in a Series B financing round in June. The company last year launched DynaFlow, a microfluidic chip for patch clamp screening, and recently said it plans to officially launch a 48-channel version of the chip October’s Society for Neuroscience annual meeting in San Diego. (See Inside Bioassays, 8/17/2004).


Cellular Genomics has named Udo Klein to the newly created position of senior vice president of drug development, the company said last week.

Klein will report to Louis Matis, president and CEO of the company, CG said. Klein formerly served as senior vice president of research and development at EntreMed. Prior to this, he was employed by Bayer for 23 years, CG said, most recently as global project leader for oncology. He earned a PhD in biochemistry from the University of Muenster in Germany.


Nanosphere, a Northbrook, Ill.-based nanobiotechnology company, announced last week that founder Chad Mirkin has received a $2.5 million award from the National Institutes of Health as one of the first recipients of the NIH Director’s Pioneer Award.

Nanosphere said that Mirkin would use the award to further develop applications for his ultra-sensitive protein detection technology.

 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.